Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (101-110 of 165) with videos related to

Pageof 17
Sort By:
Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.
Journal of the International AIDS Society|February 21, 2025
Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trialTanuja N Gengiah, Craig J Heck, Lara Lewis, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Journal of Molecular Endocrinology|January 14, 2016
Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed miceDarren S D Martin, Siobhán Leonard, Robert Devine, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 16, 2016
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSMSybil G Hosek, Bret Rudy, Raphael Landovitz, et al.
Plos One|February 23, 2010
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicideLisa C Rohan, Bernard J Moncla, Ratiya Pamela Kunjara Na Ayudhya, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
The Lancet. HIV|June 30, 2025
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trialTanuja N Gengiah, Lara Lewis, Ishana Harkoo, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV diseaseD H Shepp, C Ramirez-Ronda, L Dall, et al.
Pageof 17

Showing results (101-110 of 165) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.
Journal of the International AIDS Society|February 21, 2025
Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trialTanuja N Gengiah, Craig J Heck, Lara Lewis, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Journal of Molecular Endocrinology|January 14, 2016
Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed miceDarren S D Martin, Siobhán Leonard, Robert Devine, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 16, 2016
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSMSybil G Hosek, Bret Rudy, Raphael Landovitz, et al.
Plos One|February 23, 2010
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicideLisa C Rohan, Bernard J Moncla, Ratiya Pamela Kunjara Na Ayudhya, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
The Lancet. HIV|June 30, 2025
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trialTanuja N Gengiah, Lara Lewis, Ishana Harkoo, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV diseaseD H Shepp, C Ramirez-Ronda, L Dall, et al.
Pageof 17